Lymphocyte subset counts in CAPD patients in relation to administration of recombinant human erythropoietin and angiotensin-converting enzyme inhibitors.
Grzegorzewska
Alicja E
AE
Department of Nephrology, Karol Marcinkowski University of Medical Sciences, Poznan, Poland. Alicja_Grzegorzewska@yahoo.com
Leander
Magdalena
M
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D002216:Captopril / Q000494:pharmacology*; D004656:Enalapril / Q000494:pharmacology*; D004921:Erythropoietin / Q000494:pharmacology*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000276:immunology / Q000628:therapy*; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000187:drug effects*; D020913:Perindopril / Q000494:pharmacology*; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011994:Recombinant Proteins; D013997:Time Factors
D000806:Angiotensin-Converting Enzyme Inhibitors; D011994:Recombinant Proteins; D004921:Erythropoietin; D004656:Enalapril; D002216:Captopril; D020913:Perindopril